CRISPR Stock Stumbles on Q4 Earnings Miss and Revenue Shortfall

CRISPR Therapeutics AG faced investor disappointment when it released its fourth-quarter results, with the biotech company’s earnings and revenue both falling short of Wall Street expectations. The crispr stock’s recent performance reflects broader challenges in the gene-editing space as the company grapples with slowing revenue growth.

The Q4 Reality: How CRISPR Stock Earnings Disappointed

In the quarter ended December 2025, CRISPR Therapeutics reported a loss of $1.37 per share, worse than the Zacks consensus estimate of $1.15—marking a negative surprise of -18.85%. This represents a significant deterioration from the $0.44 per share loss a year earlier. Revenue painted an even bleaker picture, coming in at just $0.86 million against an expected $34 million, representing a 78% revenue miss. This stands in stark contrast to the prior year’s quarterly revenue of $35.69 million, signaling a dramatic year-over-year revenue decline.

The crispr stock’s market reaction and valuation will largely hinge on what management says during its earnings call. Notably, the company has struggled to beat expectations: it’s missed consensus revenue estimates in each of the last four quarters and topped earnings estimates only twice during that period. Since the beginning of 2026, crispr stock has declined approximately 7.9%, underperforming the broader market’s modest 1.4% gain shown by the S&P 500.

Looking Ahead: What’s the Consensus Calling for CRISPR Stock?

The investment community remains cautious. For the upcoming quarter, analysts consensus expects CRISPR to post a loss of $1.12 per share on revenues of $2.54 million, while the full fiscal year outlook calls for a $4.19 per share loss against $153.88 million in expected revenues. This projection assumes continued operating challenges before potential turnarounds materialize.

Earnings estimate revisions—tracking how analyst expectations shift over time—historically correlate strongly with near-term stock movements. Research confirms that stocks seeing positive estimate revisions tend to outperform those facing downward revisions. Ahead of this earnings release, crispr stock carried a mixed revision trend, currently earning a Zacks Rank #3 (Hold) rating, suggesting shares should perform roughly in line with overall market returns in the near term.

The Competitive Landscape and Industry Standing

Within the Zacks Medical - Biomedical and Genetics industry ranking, the sector currently places in the top 36% of performance among 250+ Zacks industries. Historical data shows top-tier industries outperform laggards by more than a 2-to-1 margin, offering some context for why crispr stock’s fortunes remain tied to sector dynamics.

ANI Pharmaceuticals (ANIP), a peer company in the same space, is expected to deliver a starkly different narrative. The drugmaker’s upcoming report should show earnings of $2.01 per share—up 23.3% year-over-year—with revenues projected at $233.91 million, up 22.7%. This contrast underscores the divergent trajectories within biotech, where execution quality and market timing create winners and laggards. For investors tracking crispr stock, monitoring how management executes on its pipeline and research initiatives will be crucial in determining whether negative revisions persist or sentiment begins to shift.